Tivozanib

Introduction: What is Tivozanib?

Tivozanib is a targeted therapy medication primarily used in the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs), which work by blocking specific enzymes involved in the growth and spread of cancer cells. Tivozanib is designed to inhibit the vascular endothelial growth factor (VEGF) pathway, which plays a crucial role in tumor blood vessel formation, thereby limiting the tumor's ability to grow and metastasize.

Uses of Tivozanib

Tivozanib is primarily approved for the treatment of advanced renal cell carcinoma, in adults regardless of prior systemic therapy. It is indicated for use in adults with relapsed or refractory advanced RCC following two or more prior systemic therapies, or as first-line therapy in certain cases. The drug is often considered for patients who have a specific type of kidney cancer that is resistant to other forms of therapy, making it a vital option in the oncology landscape.

How Does It Work?

Tivozanib works by targeting and inhibiting the activity of certain proteins known as tyrosine kinases. These proteins are involved in signaling pathways that promote the growth of blood vessels (angiogenesis) necessary for tumor development. By blocking these signals, Tivozanib effectively starves the tumor of the nutrients and oxygen it needs to grow, leading to reduced tumor size and slowed disease progression. In simpler terms, think of Tivozanib as a roadblock that prevents cancer cells from getting the resources they need to thrive.

Dosage and Administration

The standard dosage of Tivozanib for adults is typically 1.5 mg taken orally once daily. It is usually administered in cycles, with 21 days of treatment followed by a 7-day break. This cycle may be repeated based on the patient's response and tolerance to the medication. Dose reductions to 1.0 mg or 0.5 mg once daily may be required based on tolerability. Avoid strong CYP3A4 inducers/inhibitors; adjust dose accordingly. Tivozanib is available in tablet form, making it easy for patients to take at home. Pediatric dosing has not been established, and its use in children is not recommended.

Side Effects of Tivozanib

Like all medications, Tivozanib can cause side effects. Common side effects include:

• Fatigue
• Nausea
• Diarrhea
• Decreased appetite
• High blood pressure

Serious side effects may include:

• Posterior reversible encephalopathy syndrome (PRES)
• Arterial/venous thrombotic events
• QT prolongation
• Proteinuria
• Osteonecrosis of the jaw

Patients should report any unusual symptoms to their healthcare provider promptly.

Drug Interactions

Tivozanib may interact with several medications, which can affect how it works or increase the risk of side effects. Major drug interactions include:

• Anticoagulants (e.g., warfarin)
• Other cancer therapies (e.g., other TKIs)
• Strong CYP3A4 inhibitors (e.g., ketoconazole?reduce tivozanib to 0.89 mg); strong inducers (e.g., rifampin?increase to 2.24 mg or avoid)
• CYP3A4 substrates with narrow index (e.g., afatinib)

It is essential for patients to inform their healthcare provider about all medications, supplements, and herbal products they are taking to avoid potential interactions.

Benefits of Tivozanib

Tivozanib offers several clinical advantages, including:

• Targeted action against specific cancer pathways, leading to potentially fewer side effects compared to traditional chemotherapy.
• The ability to be used in patients who have previously undergone other treatments, providing a subsequent-line option for managing advanced RCC.
• Clinical studies have shown that Tivozanib can improve progression-free survival in patients with advanced kidney cancer. The TIVO-3 trial demonstrated superior progression-free survival (5.6 vs. 3.9 months) vs. sorafenib in third-line RCC.

Contraindications of Tivozanib

Certain individuals should avoid using Tivozanib, including:

• Pregnant or breastfeeding women, as it may harm the fetus or infant.
• Patients with a history of severe liver disease or significant cardiovascular issues.
• Individuals with known hypersensitivity to Tivozanib or any of its components. Hypersensitivity to tivozanib HCl monohydrate.

Precautions and Warnings

Before starting Tivozanib, patients should undergo specific lab tests to assess baseline and ongoing liver function and blood pressure. Regular follow-ups are essential to assess the effectiveness of the treatment and manage any side effects. Monitor for hypertension (manage with antihypertensives), thyroid dysfunction, and embryo-fetal toxicity (contraception required). Patients should also be encouraged to maintain a healthy lifestyle, including a balanced diet and regular exercise, to support their overall health during treatment.

FAQs

1. What is Tivozanib used for? Tivozanib is used to treat advanced renal cell carcinoma (kidney cancer) in adults who have not responded to other treatments.
2. How is Tivozanib taken? Tivozanib is taken orally in tablet form, usually at a dose of 1.5 mg once daily for 21 days, followed by a 7-day break.
3. What are the common side effects? Common side effects include fatigue, nausea, diarrhea, decreased appetite, and high blood pressure.
4. Can Tivozanib be used in children? No, Tivozanib is not recommended for use in children as pediatric dosing has not been established.
5. What should I do if I miss a dose? If you miss a dose, take it as soon as you remember. If it's close to the time of your next dose, skip the missed dose and continue with your regular schedule. Do not double the dose.
6. Are there any serious side effects? Yes, serious side effects can include heart problems, liver issues, severe bleeding, blood clots, and gastrointestinal perforation.
7. Can I take other medications with Tivozanib? You should inform your healthcare provider about all medications you are taking, as Tivozanib can interact with certain drugs.
8. Is Tivozanib safe during pregnancy? No, Tivozanib is contraindicated in pregnancy due to potential harm to the fetus.
9. How long will I need to take Tivozanib? The duration of treatment varies based on individual response and tolerance, and your healthcare provider will determine the best plan for you.
10. What should I do if I experience side effects? Report any side effects to your healthcare provider immediately, especially if they are severe or concerning.

Brand Names

Tivozanib is marketed under the brand name Fotivda.

Conclusion

Tivozanib represents a significant advancement in the treatment of advanced renal cell carcinoma, offering a targeted approach that can improve patient outcomes. It offers an essential option for patients who have limited choices due to prior treatments. As with any medication, it is crucial to discuss the potential benefits and risks with a healthcare provider to ensure the best possible care.